Aptevo Therapeutics Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.75M | 2.91M | 2.46M | 3.57M | 2.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.44M | 6.84M | 6.00M | 7.61M | 6.23M |
| Operating Income | -6.44M | -6.84M | -6.00M | -7.61M | -6.23M |
| Income Before Tax | -6.36M | -6.70M | -5.81M | -7.55M | -6.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.36M | -6.70M | -5.81M | -7.55M | -6.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.36M | -6.70M | -5.81M | -7.55M | -6.20M |
| EBIT | -6.44M | -6.84M | -6.00M | -7.61M | -6.23M |
| EBITDA | -6.41M | -6.80M | -5.92M | -7.56M | -6.18M |
| EPS Basic | -5.31 | -6.41 | -4.57 | -40.13 | -151.29 |
| Normalized Basic EPS | -3.32 | -3.95 | -3.84 | -20.97 | -94.55 |
| EPS Diluted | -5.31 | -6.41 | -4.57 | -40.13 | -151.29 |
| Normalized Diluted EPS | -3.32 | -3.95 | -3.84 | -20.97 | -94.55 |
| Average Basic Shares Outstanding | 1.20M | 1.06M | 946.20K | 224.90K | 41.00K |
| Average Diluted Shares Outstanding | 1.20M | 1.06M | 946.20K | 224.90K | 41.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |